Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Search strategy of CBM
Figuras y tablas -
Figure 1

Search strategy of CBM

Ir a la figura de la revisiónAbrir en una pestaña nueva

Search strategy of CNKI
Figuras y tablas -
Figure 2

Search strategy of CNKI

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 4

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 1 Number of participants with relapses at 9 months.
Figuras y tablas -
Analysis 1.1

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 1 Number of participants with relapses at 9 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 2 Number of participants with relapses at 12 months.
Figuras y tablas -
Analysis 1.2

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 2 Number of participants with relapses at 12 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 3 Number of participants with relapses at 24 months.
Figuras y tablas -
Analysis 1.3

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 3 Number of participants with relapses at 24 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 4 Number of participants with relapses.
Figuras y tablas -
Analysis 1.4

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 4 Number of participants with relapses.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 5 Number of participants with relapses of different doses.
Figuras y tablas -
Analysis 1.5

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 5 Number of participants with relapses of different doses.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 6 Number of participants with disease progression.
Figuras y tablas -
Analysis 1.6

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 6 Number of participants with disease progression.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 7 Number of participants with new T2 or GELs at 9 months.
Figuras y tablas -
Analysis 1.7

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 7 Number of participants with new T2 or GELs at 9 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 8 Number of participants with new T2 or GELs at 12 months.
Figuras y tablas -
Analysis 1.8

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 8 Number of participants with new T2 or GELs at 12 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 9 Number of participants with new T2 or GELs.
Figuras y tablas -
Analysis 1.9

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 9 Number of participants with new T2 or GELs.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 10 Number of participants with new T2 or GELs of different doses.
Figuras y tablas -
Analysis 1.10

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 10 Number of participants with new T2 or GELs of different doses.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 11 Changes of EDSS score at 24 months.
Figuras y tablas -
Analysis 1.11

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 11 Changes of EDSS score at 24 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Atorvastatin plus beta interferon versus beta interferon

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of participants with relapses at 9 months Show forest plot

1

26

Risk Ratio (M‐H, Fixed, 95% CI)

2.12 [0.28, 16.24]

2 Number of participants with relapses at 12 months Show forest plot

1

34

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.45, 2.23]

3 Number of participants with relapses at 24 months Show forest plot

1

45

Risk Ratio (M‐H, Fixed, 95% CI)

0.70 [0.36, 1.36]

4 Number of participants with relapses Show forest plot

2

71

Risk Ratio (M‐H, Fixed, 95% CI)

0.84 [0.45, 1.57]

5 Number of participants with relapses of different doses Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 20 mg/d atorvastatin

1

45

Risk Ratio (M‐H, Fixed, 95% CI)

0.70 [0.36, 1.36]

5.2 40 mg/d atorvastatin

1

16

Risk Ratio (M‐H, Fixed, 95% CI)

2.57 [0.29, 22.93]

5.3 80 mg/d atorvastatin

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

1.8 [0.19, 16.66]

6 Number of participants with disease progression Show forest plot

1

45

Risk Ratio (M‐H, Fixed, 95% CI)

0.13 [0.01, 2.22]

7 Number of participants with new T2 or GELs at 9 months Show forest plot

1

26

Risk Ratio (M‐H, Fixed, 95% CI)

4.24 [0.62, 28.76]

8 Number of participants with new T2 or GELs at 12 months Show forest plot

1

34

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.30, 3.36]

9 Number of participants with new T2 or GELs Show forest plot

2

60

Risk Ratio (M‐H, Fixed, 95% CI)

1.80 [0.66, 4.86]

10 Number of participants with new T2 or GELs of different doses Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 20 mg/d atorvastatin

1

34

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.30, 3.36]

10.2 40 mg/d atorvastatin

1

16

Risk Ratio (M‐H, Fixed, 95% CI)

3.86 [0.50, 29.55]

10.3 80 mg/d atorvastatin

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

4.5 [0.64, 31.60]

11 Changes of EDSS score at 24 months Show forest plot

1

45

Mean Difference (IV, Fixed, 95% CI)

‐0.2 [‐0.84, 0.44]
Figuras y tablas -
Comparison 1. Atorvastatin plus beta interferon versus beta interferon
Ir a la tabla de la revisión